Tirapazamine
- Generic Name
- Tirapazamine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C7H6N4O2
- CAS Number
- 27314-97-2
- Unique Ingredient Identifier
- 1UD32YR59G
- Background
Tirapazamine, also known as SR-4233, is an experimental anticancer drug that is activated in hypoxic conditions. This activation is very useful as this hypoxic state is found in human solid tumors in a common phenomenon known as tumor hypoxia. Hence, tirapazamine is solely activated in those hypoxic areas of solid tumors. It is important to take into conside...
- Indication
For the treatment of head and neck cancer.
- Associated Conditions
- -
- Associated Therapies
- -
TATE Versus TACE in Intermediate Stage HCC
- Conditions
- Interventions
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Teclison Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT03145558
- Locations
- πΊπΈ
University of California, Irvine, Irvine, California, United States
πΊπΈOregon Health Science University, Portland, Oregon, United States
πΊπΈMedical College of Wisconsin, Milwaukee, Wisconsin, United States
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Teclison Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT02174549
- Locations
- πΊπΈ
Stanford University, Palo Alto, California, United States
πΊπΈUniversity of Pennsylvania, Philadelphia, Pennsylvania, United States
Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 402
- Registration Number
- NCT00262821
- Locations
- πΊπΈ
Saint Joseph's Hospital of Atlanta, Atlanta, Georgia, United States
πΊπΈArthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
πΊπΈThomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
TRACE: Tirapazamine-Radiation And Cisplatin Evaluation
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 317
- Registration Number
- NCT00174837
- Locations
- π³πΏ
sanofi-aventis New Zealand administrative office, Macquarie Park, New Zealand
π¨π³Sanofi-Aventis Administrative Office, Taipei, Taiwan
Tirapazamine, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
- Conditions
- First Posted Date
- 2004-12-09
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 22
- Registration Number
- NCT00098995
- Locations
- π¦πΊ
Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
π¨π¦Princess Margaret Hospital, Toronto, Ontario, Canada
Tirapazamine Plus Cyclophosphamide in Treating Children With Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2004-09-13
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT00003288
- Locations
- πΊπΈ
Hackensack University Medical Center, Hackensack, New Jersey, United States
πΊπΈUniversity of Mississippi Medical Center, Jackson, Mississippi, United States
πΊπΈUniversity of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
S9717 Tirapazamine Plus Cisplatin in Treating Patients With Metastatic, Recurrent, or Refractory Cervical Cancer
- First Posted Date
- 2004-06-24
- Last Posted Date
- 2012-06-14
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 56
- Registration Number
- NCT00003369
- Locations
- πΊπΈ
University of Mississippi Medical Center, Jackson, Mississippi, United States
πΊπΈJonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
πΊπΈCCOP - Atlanta Regional, Atlanta, Georgia, United States
Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-04-06
- Last Posted Date
- 2014-06-20
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 63
- Registration Number
- NCT00002774
- Locations
- πΊπΈ
Veterans Affairs Medical Center - Palo Alto, Palo Alto, California, United States
πΊπΈStanford University Medical Center, Stanford, California, United States
S0004: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-04-02
- Last Posted Date
- 2012-10-04
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 30
- Registration Number
- NCT00006487
- Locations
- πΊπΈ
MBCCOP - Gulf Coast, Mobile, Alabama, United States
πΊπΈUSC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
πΊπΈJonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00017459
- Locations
- πΊπΈ
University of Florida Health Science Center - Jacksonville, Jacksonville, Florida, United States
πΊπΈLos Angeles County Harbor-UCLA Medical Center, Torrance, California, United States
πΊπΈJohn Wayne Cancer Institute, Santa Monica, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.